In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report).

Nisa Investment Advisors LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 16,500 shares of the ...

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

10x Genomics excels in single-cell and spatial ... Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate ...

Cathie Wood's ARK ETFs have made their daily trades public for Wednesday, 29 January 2025, showcasing a series of strategic moves in the tech and biotech sectors. The most significant purchase was in ...

10x Genomics Inc is a life science technology company ... Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems.

Investing.com -- Shares of 10X Genomics (NASDAQ:TXG) climbed 7% as the company reported preliminary fourth-quarter sales that surpassed analyst expectations. The life sciences company, known for ...

These ratings convey expectations for the relative performance of 10x Genomics compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value.